Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

STAVUDINE; LAMIVUDINE; EFAVIRENZ

STAVUDINE; LAMIVUDINE; EFAVIRENZ

Standard Dose
40MG; 150MG; 600MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: None (Tentative Approval)
Summary

Approval overview STAVUDINE; LAMIVUDINE; EFAVIRENZ is listed in Drugs@FDA under application 022097 (NDA).

Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient STAVUDINE; LAMIVUDINE; EFAVIRENZ Form and strength TABLET; ORAL - 40MG; 150MG; 600MG Sponsor STRIDES ACROLAB Submission history Latest submission status date: 2007-06-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview STAVUDINE; LAMIVUDINE; EFAVIRENZ is listed in Drugs@FDA under application 022097 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient STAVUDINE; LAMIVUDINE; EFAVIRENZ Form and strength TABLET; ORAL - 40MG; 150MG; 600MG Sponsor STRIDES ACROLAB Submission history Latest submission status date: 2007-06-01 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.